Reig Jofre reaches € 200 million in revenue and closes 2019 with a growth of 11% in sales and 20% in EBITDA

  • The turnover was € 200.2 million (+ 11%), driven by the organic growth of all business units and the new product portfolio in health and joint pain acquired on July 1 and integrated into the Specialty Pharmacare business unit, that grew 41%
  • Pharmaceutical Technologies and Consumer Healthcare business units contributed positive growth of 2% and 6% respectively
  • Reig Jofre generated 45% of its sales in Spain, representing sales in the rest of Europe 45% and 10% in other countries. The most outstanding growth occurred in Spain since the new products portfolio incorporated contributed 87% of its sales in this market. The next growing markets were Finland and Japan